1. Introduction {#sec0005}
===============

Most women diagnosed with oestrogen receptor positive (ER+ve) breast cancer in England are prescribed endocrine therapy (ET). ET decreases recurrence and increases survival \[[@bib0005]\] and is the current standard treatment for patients with ER+ve disease in both early and metastatic breast cancer \[[@bib0010]\]. Adherence to ET was reported to be between 40% and 70% over a five year treatment period \[[@bib0015],[@bib0020]\].

In England ET is commonly prescribed for a duration of five years \[[@bib0025]\]. It is usually initiated in a hospital setting, but the majority of repeat prescriptions are issued in primary care. It has been possible to link cancer registrations in England with prescriptions issued in primary care using the Clinical Practice Research Datalink (CPRD)\[[@bib0030]\], but the CPRD covers only around 7% of the population. Furthermore, it includes only patients registered with participating general practices. If a patient moves, further prescriptions may not recorded. This has hampered studies of drugs that are used for long periods of time, such as ET in women with breast cancer \[[@bib0035]\].

The Primary Care Prescription Database (PCPD) is an administrative database used to calculate reimbursement for prescriptions dispensed by community pharmacies. It contains demographic and drug information categorised according to the British National Formulary (BNF) version 68 \[[@bib0040]\]. The NHS Business Services Authority (NHSBSA) has partnered with the National Cancer Registration and Analysis Service (NCRAS), allowing cancer registration data to be linked with the PCPD. To assess the epidemiological research potential of the PCPD we have evaluated the level of prescribing of ET and selected other drugs in women with breast cancer in England.

2. Materials and methods {#sec0010}
========================

Cancer registration is managed by NCRAS and data on all patients diagnosed with cancer in England are collected. Cancer registrations for women diagnosed with breast cancer (ICD-10 code C50) in England between 1st January 1995 and 31st July 2015 with no previous cancer were identified. Women who died before 1st April 2015, those living outside of England and those with a date of death before the prescription was processed were excluded. This is because, in the PCPD, the date of the prescription is the date it was processed by the NHSBSA and in very few cases (0.3% of prescription items in the entire dataset \[[@bib0040]\]), this is after the patient's death. We collected information on dates of birth, stage, ER and progesterone receptor (PR) status.

Ages were calculated as of the 1st April 2015 and grouped. We calculated the difference in years between the date of breast cancer diagnosis and the end of the reference period (31st July 2015). The confidence intervals were determined using the Wilson score methodology \[[@bib0045]\].

The cancer registrations were linked to ET prescriptions in the PCPD during a reference period of April to July 2015 using pseudonymised identifiers derived from NHS number and date of birth. For women recorded with early stage ER+ve disease diagnosed during 2010--2015 the registrations were also linked to prescriptions of the following drugs if they were co-prescribed with ET during the reference period: analgesics, statins, oral hypoglycaemics, and anticoagulents. The same was done for oral bisphosphonates co-prescribed with aromatase inhibitors (AIs). To estimate prescribing in the general population, age-weighted averages of individuals prescribed these drugs were calculated. These averages were weighted by individuals in the PCPD by each year of age and were restricted to those having received any prescription during the reference period, excluding individuals prescribed AIs (for the oral bisphosphonates estimates) and ET (for all other estimates). Sex was not specified as it is not included in the PCPD.

3. Results {#sec0015}
==========

Among 369 277 survivors of breast cancer diagnosed during the years 1995--2015, 61% had ER unknown; 34% had ER+ve; 5% had ER-ve; and 0.02% had ER borderline disease. The average age of women with ER+ve disease was 64. Overall, 37% of the study population were prescribed ET during the reference period. The commonest drugs were tamoxifen (34% of prescriptions) and AIs (64% of prescriptions). For women recorded with ER+ve disease, 69% were prescribed ET compared with 42% of women with borderline ER, 5% of women with ER-ve disease, and 23% of women with unknown ER status.

Among women recorded with ER+ve disease, 81% of those diagnosed after 31st July 2010 (i.e. within the previous five years at the time of the reference period) were prescribed ET compared with 46% of women with borderline ER status and only 6% of women with ER-ve disease ([Fig. 1](#fig0005){ref-type="fig"} panel A).Fig. 1Prescriptions of endocrine therapy during April-July 2015 among women diagnosed with breast cancer in England during 1995--2015.This figure presents the prescribing of endocrine therapy by ER status and time since diagnosis in Panel A. Panel B presents the prescribing of endocrine therapy by time since diagnosis in ER+ve women. Panels C and D present the prescribing of tamoxifen and aromatase inhibitors, respectively, by age. Confidence intervals were determined using the Wilson score methodology.Fig. 1

Among women recorded with ER+ve disease 59% of those diagnosed with breast cancer after 31st July 2014 (i.e. during the year prior to the reference period) were prescribed ET as were 90%, 88%, 87% and 85% respectively of women diagnosed during the 2nd, 3^rd^, 4^th^ and 5^th^ years previously ([Fig. 1](#fig0005){ref-type="fig"} panel B). For women diagnosed before this, the percentage of women still being prescribed ET during the reference period decreased progressively down to 7% during the 13^th^ year before the reference period, and then increased slowly to 24% in the 20^th^ year before the reference period.

For women recorded as ER+ve and aged less than 55, tamoxifen was the commonest drug and was prescribed to 55% of them ([Fig. 1](#fig0005){ref-type="fig"} panel C), while for ER+ve women aged 55 and older AIs were the commonest drug and were prescribed to 52% of them ([Fig. 1](#fig0005){ref-type="fig"} panel D).

Among women recorded with ER+ve disease, 22% of women who were prescribed AIs were co-prescribed oral bisphosphonates (3% in the general population). Other drugs commonly co-prescribed with ET to ER+ve women were analgesics (27% compared to 21% in the general population) and statins (24% compared to 24% in the general population). Much smaller percentages of women were co-prescribed oral hypoglycaemics (7% compared to 8% in the general population) or anticoagulents (4% compared to 4% in the general population).

4. Discussion {#sec0020}
=============

This proof of concept study has demonstrated the ability of the PCPD to identify prescriptions of ET issued in primary care to women in the years following a diagnosis of breast cancer. This is the first such data to become available for the entire population of England.

Most women with early breast cancer will not usually be prescribed ET until their other cancer treatments are completed, which usually takes a few months. Also, the initial ET prescription may be issued in hospital. Therefore, the best estimate of the overall proportion of ER+ve women who are prescribed ET is the percentage of women recorded in the PCPD who received it during the second year after their breast cancer diagnosis. During this period ET prescriptions were issued to 90% of women recorded as ER+ve.

Prescribing of ET decreased after around 5 years after breast cancer diagnosis which was expected as, during the time-period studied, guidelines for ET in early breast cancer recommended that it be prescribed for five years. ET is also recommended for metastatic breast cancer, so it was expected that ET prescriptions would be issued for a percentage of women in the second decade after breast cancer diagnosis, mostly for the treatment of metastatic disease.

A small proportion of ER-ve patients in the cohort were prescribed ET. A quarter of these women were recorded as PR positive, and the prescription of ET is in accord with evidence that tamoxifen increases survival in patients with ER-ve/PR+ve cancers \[[@bib0050]\].

The choice of ET type is related to menopausal status, with tamoxifen suitable at any age \[[@bib0025]\] but AIs suitable only for postmenopausal women or (much less commonly), younger women rendered postmenopausal. The patterns of ET prescriptions in the PCPD were in accordance with these scenarios.

The analysis of other drugs co-prescribed with endocrine therapy in ER+ve women with early breast cancer provides insight into the use of oral bisphosphonates in managing AI-associated bone loss \[[@bib0025]\] and of analgesics for the possible treatment of AI-induced arthralgia \[[@bib0055]\], while prescriptions of drugs associated with non-breast-cancer comorbidities such as statins and anticoagulents to treat cardiovascular disease and oral hypoglycaemics for diabetes were lower or similar to the general population.

ET has contributed substantially to patient survival \[[@bib0060],[@bib0065]\] and prior to the linkage of PCPD to cancer registration data in England, ET prescribing in women with breast cancer could not be reliably captured for the entire population \[[@bib0070],[@bib0035]\]. A key strength of the PCPD is its national and near complete coverage \[[@bib0040]\]. The coverage of the study population by the PCPD was high, with 86% of patients having received a prescription during the reference period. Some patients may have been missed due to not receiving a prescription during the short time frame covered by the reference period. An additional limitation of the PCPD is that age is missing for approximately 20% of prescriptions, potentially impacting the general population estimates for the co-prescribed drugs. Furthermore, as osteoporosis increases with age and women have higher rates of osteoporosis than men \[[@bib0075]\], our estimate of the prescribing rate of bisphosphonates is likely to underestimate the rate in older women and overestimate the rate in the entire population.

Prescribing was consistent with clinical practice and in accordance with ER status, patient age, and anticipated treatment duration. This study therefore provides confidence in the use of the PCPD for epidemiological purposes. A project is underway within PHE with the intention of making the prescriptions dataset available for request via the Office for Data Release \[[@bib0040]\] (ODR). This dataset has the potential for many applications, including providing a proxy for multimorbidity, as well as an insight into trends in prescribing both before and after cancer diagnosis and in end of life care. It could also be used to understand geographical differences in prescribing, adherence to guidance and to identify patterns in prescribing which could potentially highlight opportunities for earlier diagnosis. In the future, the PCPD should bridge a substantial gap in the knowledge of therapies that are not hospital based, especially those such as ET where primary care based prescription is the norm and continues over time.
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